ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Classification of Osteosarcoma Based on Immunogenomic Profiling

Wang, Xinwen; Wang, Liangming; Xu, Weifeng; Wang, Xinwu; Ke, Dianshan; Lin, Jinluan; Lin, Wanzun*; Bai, Xiaochun*复旦大学; 南方医科大学; 郑州大学; 1
Frontiers in Cell and Developmental Biology2021-7-16DOI: 10.3389/fcell.2021.696878
13被引9阅读
引用收藏
分享

摘要

Accumulating evidence has supported that osteosarcoma is heterogeneous, and several subtypes have been identified based on genomic profiling. Immunotherapy is revolutionizing cancer treatment and is a promising therapeutic strategy. In contrast, few studies have identified osteosarcoma classification based on immune biosignatures, which offer the optimal stratification of individuals befitting immunotherapy. Here, we classified osteosarcoma into two clusters: immunity high and immunity low using the single-sample gene-set enrichment analysis and unsupervised hierarchical clustering. Immunity_H subtype was associated with high immune cells infiltration, a favorable prognosis, benefit to immunotherapy, high human leukocyte antigen gene expression, and activated immune signal pathway indicating an immune-hot phenotype. On the contrary, the Immunity_L subtype was correlated with low immune cell infiltration, poor prognosis, and cancer-related pathway, indicating an immune-cold phenotype. We also identified TYROBP as a key immunoregulatory gene associated with CD8(+) T cell infiltration by multiplex immunohistochemistry. Finally, we established an immune-related prognostic model that predicted the survival time of osteosarcoma. In conclusion, we established a new classification system of osteosarcoma based on immune signatures and identified TYROBP as a key immunoregulatory gene. This stratification had significant clinical outcomes for estimating prognosis, as well as the immunotherapy of osteosarcoma patients.

学科与关键词

关键词
osteosarcomaimmune subtypeimmune checkpoint inhibitorsTYROBPprognosis
相关
加载中…
  • Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures
    Tan, Jianye; Feng, Xuhui; Wu, Hangxing; Yang, Bingsheng; Shi, Meiling; Xie, Chao; Su, Zexin; Li, Lin; Luo, Mengliang; Zuo, Zhijie; Zhu, Shuang; Yang, Jiancheng*; Lin, LijunJournal of Immunology Research, 2022, 2022: 6568278.被引 2
  • Identification of prognostic biomarkers associated with metastasis and immune infiltration in osteosarcoma
    Yang, Bingsheng; Su, Zexin; Chen, Guoli; Zeng, Zhirui; Tan, Jianye; Wu, Guofeng; Zhu, Shuang*; Lin, Lijun*Oncology Letters, 2021, 21(3): 180.被引 20
  • Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma
    Li, Qinwen; Huang, Xiaoyan; Zhao, Youfang*Cancer Biotherapy and Radiopharmaceuticals, 2023.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Cell and Developmental Biology
发表日期
2021-07-16
卷期
第 9 卷
页码
696878
DOI
10.3389/fcell.2021.696878
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Jiangmen Medical and Health Technology Plan Project [2019B003]

作者

  • W

    Wang, Xinwen (第一作者)

    southern med univ

  • W

    Wang, Liangming

    2 · fujian med univ

查看全部 8 位作者收起作者
  • X

    Xu, Weifeng

    zhengzhou univ

  • W

    Wang, Xinwu

  • K

    Ke, Dianshan

  • L

    Lin, Jinluan

    1 · fujian med univ

  • L

    Lin, Wanzun (通讯)

    fudan univ

  • B

    Bai, Xiaochun (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417